# US 2024/0190964 A1 · Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0190964 A1
- Document ID: US20240190964A1
- Status: Published application
- Kind: A1
- Application number: 18/510,228
- Filed: 2023-11-15
- Published: 2024-06-13
- Earliest claimed: 2021-06-04
- Assignees: Kymab Limited
- Applicants: Kymab Limited
- Inventors: Anthea NEWTON; Cintia Cristina PALU; Sonia QUARATINO; Richard Charles Alfred SAINSON; Cecilia DEANTONIO; Matthew Stephen WAKE
- Web page: https://patentgrep.com/patent/US20240190964A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

This invention relates to compositions and methods for the treatment of cancer, in particular difficult-to-treat cancers. More specifically, the present invention relates to compositions and methods for the treatment of PD-L1 negative or PD-L1 low expressing cancers using a modulator of ICOS, such as an anti-ICOS antibody, either alone or in combination with other agents, such as an anti-PD-L1 antibody.

## Claims

### Claim 1

A method of treating cancer in a patient, wherein the patient has a PD-L1 negative tumour or a tumour with low PD-L1 expression, comprising administering to the patient a modulator of ICOS.

### Claim at position 2

2-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, cervical cancer, anogenital cancer, melanoma, non small cell lung cancer, diffuse large B-cell lymphoma, breast cancer (e.g. triple negative breast cancer), penile cancer, pancreatic cancer, and oropharyngeal cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the tumour is HPV (Human papillomavirus) positive.

### Claim at position 5

12-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, comprising administering a single dose of the ICOS modulator optionally followed by multiple doses of the PD-L1 inhibitor.

### Claim at position 7

19-21. (canceled)

### Claim 22 (depends on 1)

The method of claim 1, wherein the ICOS modulator is an anti-ICOS antibody comprising a VH domain comprises a set of heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, wherein
a. HCDR1 is the STIM003 HCDR1 having amino acid sequence SEQ ID NO: 405,
b. HCDR2 is the STIM003 HCDR2 having amino acid sequence SEQ ID NO: 406,
c. HCDR3 is the STIM003 HCDR3 having amino acid sequence SEQ ID NO: 407; and/or
wherein the VL domain comprises a set of light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein:
d. LCDR1 is the STIM003 LCDR1 having amino acid sequence SEQ ID NO: 412,
e. LCDR2 is the STIM003 LCDR2 having amino acid sequence SEQ ID NO: 413,
f. LCDR3 is the STIM003 LCDR3 having amino acid sequence SEQ ID NO: 414.

### Claim 23 (depends on 1)

The method of claim 1, wherein the ICOS modulator is an anti-ICOS antibody comprising a VH domain amino acid sequence is SEQ ID NO: 408 and/or wherein the VL domain amino acid sequence is SEQ ID NO: 415.

### Claim at position 10

24-29. (canceled)

### Claim 30 (depends on 1)

The method of claim 1, wherein antibody comprises an antibody constant region, optionally wherein the constant region comprises a human heavy and/or light chain constant region, optionally wherein the constant region is Fc effector positive.

### Claim 31 (depends on 1)

The method of claim 1, wherein the antibody is a multispecific antibody.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the PD-L1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of atezoliumab (Roche), avelumab (Merck), durvalumab/Medi4736 (Medimmune), KN035, CK-301, AUNP12, CA-170, BMS-936559/MDX-1105 (BMS), FAZ-053 M7824, ABBV-368, LY-3300054, GNS-1480, YW243.55.570, REGN3504 and SP263.

### Claim at position 15

34-36. (canceled)

### Claim 37

A method of treating cancer in a patient comprising administering to the patient a modulator of ICOS, wherein:
a. the patient has a PD-L1 negative tumour or a tumour with low PD-L1 expression; or
b. the patient has previously received treatment for the cancer and the patient did not respond to the previous treatment or ceased responding to the previous treatment, wherein the previous treatment for the cancer was a PD-L1 inhibitor.

### Claim 38 (depends on 37)

The ICOS modulator for use as claimed in claim 37, wherein the ICOS modulator is for use in combination with a PD-L1 inhibitor, optionally wherein the ICOS modulator is an agonistic anti-ICOS antibody, optionally wherein the ICOS modulator is a bispecific antibody that is an anti-ICOS agonist and an anti-PD-L1 antagonist or a bispecific antibody that is an anti-ICOS agonist and an anti-PD-1 antagonist.

### Claim 39

(canceled)

### Claim 40 (depends on 37)

The method of claim 37, wherein the ICOS modulator is an anti-ICOS antibody that binds the extracellular domain of human and/or mouse ICOS, comprising:
an antibody VH domain comprising complementarity determining regions (CDRs) HCDR1, HCDR2 and HCDR3, and
an antibody VL domain comprising complementarity determining regions LCDR1, LCDR2 and LCDR3, wherein:
HCDR1 is the HCDR1 of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009, or comprises that HCDR1 with 1, 2, 3, 4 or 5 amino acid alterations,
HCDR2 is the HCDR2 of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009, or comprises that HCDR2 with 1, 2, 3, 4 or 5 amino acid alterations, and/or
HCDR3 is the HCDR3 of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009 or comprises that HCDR3 with 1, 2, 3, 4 or 5 amino acid alterations; and/or
wherein LCDR1 is the LCDR1 of STIM001, STIM002, STIM002-B, STIM003, STIM004 STIM005, STIM006, STIM007, STIM008 or STIM009, or comprises that LCDR1 with 1, 2, 3, 4 or 5 amino acid alterations,
LCDR2 is the LCDR2 of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009, or comprises that LCDR2 with 1, 2, 3, 4 or 5 amino acid alterations, and/or
LCDR3 is the LCDR3 of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009 or comprises that LCDR3 with 1, 2, 3, 4 or 5 amino acid alterations.

### Claim 41 (depends on 37)

The method of claim 37, wherein the antibody comprises an antibody VH domain which is the VH domain of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009, or which has an amino acid sequence at least 90% identical to the antibody VH domain sequence of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009; and/or wherein the antibody comprises an antibody VL domain which is the VL domain of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009, or which has an amino acid sequence at least 90% identical to the antibody VL domain sequence of STIM001, STIM002, STIM002-B, STIM003, STIM004, STIM005, STIM006, STIM007, STIM008 or STIM009.

### Claim 42

A method of treating cancer in a patient who has previously received treatment for the cancer, wherein the previous treatment for the cancer was administration of a PD-L1 inhibitor and the patient did not respond to the previous treatment or ceased responding to the previous treatment, and wherein the patient has a PD-L1 negative tumour or a tumour with low PD-L1 expression, comprising administering to the patient a modulator of ICOS.

### Claim 43 (depends on 42)

The method of claim 42, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, cervical cancer, anogenital cancer, melanoma, non small cell lung cancer, diffuse large B-cell lymphoma, breast cancer (e.g. triple negative breast cancer), penile cancer, pancreatic cancer, and oropharyngeal cancer.

### Claim 44 (depends on 42)

The method of claim 42, wherein the VH domain comprises a set of heavy chain complementarity determining regions (HCDRs) HCDR1, HCDR2 and HCDR3, wherein
a. HCDR1 is the STIM003 HCDR1 having amino acid sequence SEQ ID NO: 405,
b. HCDR2 is the STIM003 HCDR2 having amino acid sequence SEQ ID NO: 406,
c. HCDR3 is the STIM003 HCDR3 having amino acid sequence SEQ ID NO: 407; and/or
wherein the VL domain comprises a set of light chain complementarity determining regions (LCDRs) LCDR1, LCDR2 and LCDR3, wherein:
d. LCDR1 is the STIM003 LCDR1 having amino acid sequence SEQ ID NO: 412,
e. LCDR2 is the STIM003 LCDR2 having amino acid sequence SEQ ID NO: 413,
f. LCDR3 is the STIM003 LCDR3 having amino acid sequence SEQ ID NO: 414.

### Claim 45 (depends on 42)

The method of claim 42, wherein the VH domain amino acid sequence is SEQ ID NO: 408 and/or wherein the VL domain amino acid sequence is SEQ ID NO: 415.

### Claim 46 (depends on 42)

The method of claim 42, wherein the cancer is selected from the group consisting of head and neck squamous cell carcinoma, cervical cancer, anogenital cancer, melanoma, non small cell lung cancer, diffuse large B-cell lymphoma, breast cancer (e.g. triple negative breast cancer), penile cancer, pancreatic cancer, and oropharyngeal cancer.

### Claim 47 (depends on 42)

The method of claim 42, wherein the PD-L1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of atezoliumab (Roche), avelumab (Merck), durvalumab/Medi4736 (Medimmune), KN035, CK-301, AUNP12, CA-170, BMS-936559/MDX-1105 (BMS), FAZ-053 M7824, ABBV-368, LY-3300054, GNS-1480, YW243.55.S70, REGN3504 and SP263.

### Claim 48 (depends on 42)

The method of claim 42, wherein the antibody is a multispecific antibody.
